Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Aug 1;22(1):837.
doi: 10.1186/s12885-022-09946-x.

Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer

Beomyoung Cho  1 , Maria Pérez  2 , Donna B Jeffe  2   3 , Matthew W Kreuter  4 , Julie A Margenthaler  3   5 , Graham A Colditz  3   5 , Ying Liu  6   7
Affiliations
Clinical Trial

Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer

Beomyoung Cho et al. BMC Cancer. .

Abstract

Background: Despite benefits of endocrine therapy (ET) for patients with hormone-receptor (HR)-positive breast cancer, many patients do not initiate or discontinue ET against recommendations.

Methods: We identified variables associated with ET initiation and continuation, analyzing pooled data from two longitudinal studies at a National Cancer Institute comprehensive cancer center in St. Louis, Missouri. The sample included 533 women with newly diagnosed, non-metastatic, HR-positive breast cancer who completed interviews at enrollment and 6, 12, and 24 months after definitive surgical treatment. Logistic regression models estimated the adjusted odds ratio and 95% confidence interval (aOR [95% CI]) for each of self-reported ET initiation by the 12-month interview and continuation for ≥12 months by the 24-month interview in association with self-reported diabetes, elevated depressed mood, menopausal-symptom severity and obesity, adjusting for race, age, insurance status, chemotherapy, and radiation therapy.

Results: Overall, 81.4% (434/533) of patients initiated ET, and 86.5% (371/429) continued ET ≥12 months. Patients with diabetes had lower odds of initiating ET (0.50 [0.27-0.91]). Patients reporting greater menopausal-symptom severity had lower odds of continuing ET (0.72 [0.53-0.99]).

Conclusion: Efforts to increase ET initiation among patients with diabetes and better manage severe menopausal symptoms among ET users might promote ET continuation.

Clinical trial information: ClinicalTrials.gov : #NCT00929084.

Keywords: Breast cancer; Depression; Diabetes; Hormone therapy; Menopausal symptoms; Obesity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Inclusion/exclusion procedure of study sample
See this image and copyright information in PMC

References

    1. American Cancer Society . Breast Cancer Facts & Figures 2019-2020. Atlanta: American Cancer Society, Inc.; 2019.
    1. Farias AJ, Du XL. Racial differences in adjuvant endocrine therapy use and discontinuation in association with mortality among Medicare breast Cancer patients by receptor status. Cancer Epidemiol Biomark Prev. 2017;26(8):1266–1275. doi: 10.1158/1055-9965.EPI-17-0280. - DOI - PMC - PubMed
    1. Wheeler SB, Kohler RE, Reeder-Hayes KE, Goyal RK, Lich KH, Moore A, Smith TW, Melvin CL, Muss HB. Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors. J Cancer Surviv. 2014;8(4):603–610. doi: 10.1007/s11764-014-0365-3. - DOI - PMC - PubMed
    1. Livaudais JC, Hershman DL, Habel L, Kushi L, Gomez SL, Li CI, Neugut AI, Fehrenbacher L, Thompson B, Coronado GD. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2012;131(2):607–617. doi: 10.1007/s10549-011-1762-1. - DOI - PMC - PubMed
    1. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–4128. doi: 10.1200/JCO.2009.25.9655. - DOI - PMC - PubMed

Publication types

Substances

Associated data